Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model [Accessibility Statement] Skip NavigationIn a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy® and Ozempic®) across key metrics, including weight stabilization, glucose tolerance, liver weight r ...

Core Viewpoint - Novo Nordisk has initiated a U.S. patent lawsuit against Hims & Hers, targeting the sale of compounded versions of its weight-loss drug Wegovy, marking a significant escalation in its legal strategy against compounding pharmacies [1][2]. Legal Context - This lawsuit is Novo's first against a compounding pharmacy in the U.S. regarding Wegovy, coinciding with the FDA's announcement that the active ingredient semaglutide is no longer in short supply, which has lessened concerns about public backlash from patent enforcement [2][3]. - Hims & Hers recently launched a $49 compounded version of Wegovy but quickly retreated after the FDA indicated it would take action against the company [3]. Financial Implications - Hims & Hers has projected its total revenue to exceed $2.3 billion by 2025 and aims for $6.5 billion by 2030, indicating rapid growth in the telehealth sector [4]. Regulatory Environment - U.S. regulations permit compounding pharmacies to produce and sell brand-name medicines if they are in short supply, but without a shortage, compounding is generally allowed only for customized patient needs [5]. - The FDA had previously listed semaglutide as in short supply in 2022, which facilitated the rise of compounding, but declared the shortage over in February 2025 [6]. Previous Legal Actions - Novo Nordisk has previously filed lawsuits against smaller compounding pharmacies for selling unsafe or falsely advertised Wegovy "knockoffs," focusing on safety and trademark rights during the semaglutide shortage [7].

The stock has climbed in the triple digits over the past three years.Eli Lilly (LLY 1.28%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price explode higher. GLP-1 drugs have been in great demand as they've helped people quickly and safely shed pounds.Now, though, after Lilly stock's 200% increase over three years, you may be wondering if the growth story has fully played out or if there' ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.Getty Images Precious metals and crypto to the labor market and $1T club! Dive into the latest hot themes in the SA Sentiment Survey for February, which explores the investing decisions of the Seeking Alpha community. Click here to take the poll and don't forget to share your thoughts in the WSB comments section. Good morning! Here's the latest in trending:Seahawks prevail: The Super ...

Over the past few years, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been dominating one of the biggest growth markets in the pharma industry: the weight loss drug market. Demand for these drugs has soared -- even resulting in product shortages at times -- and analysts expect the market to reach nearly $100 billion by 2030. Novo was first to market with semaglutide, commercialized as Ozempic for type 2 diabetes and Wegovy for weight loss. Lilly then joined the market with tirzepatide, sold as ...

Within a single day, the two biggest makers of modern weight-loss drugs signaled different paths for the booming market. Novo Nordisk and Eli Lilly offered contrasting views on where business is headed, sharpening investor focus on demand, supply, and pricing.The divergence came within 19 hours, hinting at uncertainty in a market that has reshaped diabetes and obesity care. The companies dominate sales of GLP-1 medicines used for weight loss and diabetes. Their comments suggest different assumptions about h ...

Core Viewpoint - Hims & Hers faces legal action from Novo Nordisk after announcing plans to launch a cheaper version of Novo's weight loss pill, leading to significant stock price fluctuations [1][2] Group 1: Stock Performance - Hims & Hers stock initially spiked by 15% following the announcement but ended the trading session down 3.8%, reaching a 12-month low [1] - In premarket trading on Friday, shares fell an additional 6.7% after Novo Nordisk labeled the action as "illegal" [1] Group 2: Product Launch Details - Hims plans to introduce a Wegovy-style pill containing semaglutide, priced at $49 for the first month with a subscription, increasing to $99 thereafter [2] - This pricing is significantly lower than Novo Nordisk's starting dose price of $149 on its NovoCare website [2]

Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ... ...

Core Viewpoint - Shares in Novo Nordisk have significantly declined following a forecast indicating a drop in sales and profit growth for 2026, which is below analyst expectations due to pricing and patent expiry challenges [1][2]. Sales and Profit Outlook - Novo Nordisk anticipates a potential sales decline of up to 13% at constant exchange rates (CER) for the upcoming year, marking the first sales decrease in years [1] - Adjusted operating profit growth is also expected to decrease by 13% at CER [1] - The 2026 guidance for sales and operating profit is projected to be 8% and 10% below consensus estimates, respectively, at the midpoints [2] Recent Performance - In 2025, Novo reported CER sales growth of 10%, reaching DKr 309 billion [3]. Pricing and Policy Impact - The weak outlook for 2026 is attributed to pricing pressures in the US, particularly due to President Trump's Most Favored Nation (MFN) policy, which led to a pricing deal that significantly reduced prices for its semaglutide brands [4] - The agreement was made in the context of potential tariffs on imported drugs, which posed a significant risk to Novo, as the US is its most profitable market [5] Patent Expiry and Competition - Patent expiries for semaglutide in markets such as Brazil, Canada, and China have negatively impacted the sales outlook for 2026 [6] - Increased competition from Eli Lilly's products, including tirzepatide brands Zepbound and Mounjaro, has further constrained Novo's market share in the obesity treatment sector [6] Market Position - Novo Nordisk has seen a decline in its market value, slipping down the rankings of the most valuable companies in Europe, while Eli Lilly has achieved a trillion-dollar market cap, highlighting the contrasting fortunes of the two companies [7]

Novo Nordisk (NVO) shares crashed on Tuesday after the Danish drugmaker issued a sobering outlook for 2026 that caught Wall Street flat-footed. According to the pharma giant, its top- and bottom-line growth will decelerate this year as its “Most Favored Nations” agreement with the U.S. lowers weight-loss drug prices in its largest market. More News from Barchart At the time of writing, Novo Nordisk stock is trading some 20% below its year-to-date high. www.barchart.com What This 2026 Outlook Really M ...